Schering-Plough names communications director

Share this article:
Schering-Plough named Pfizer's Catherine Cantone director, global product communications and advocacy relations.

Cantone, formerly director of public relations at Pfizer, reports to vice president of global product communications and advocacy development Mary-Frances Faraji, herself a Pfizer alum. She will be responsible for global product communications and advocacy on Schering-Plough's arthritis treatment Remicade, as well as the company's oncology franchise. Cantone replaces Joy Schmitt, who is moving abroad.

The oncology franchise includes Temodar, for brain cancer, and Intron, for renal cell carcinoma, in the US. The firm also markets Caelyx, for ovarian cancer, Kaposi's sarcoma and metastatic breast cancer, outside the US.

Remicade posted strong growth in the second quarter, with revenues rising 31% to $307 million, contributing to an overall 11% gain, year-on-year. The drug recently won EU approval as a monotherapy in the treatment of psoriatic arthritis.

 “We're very pleased to have someone of Cathy's caliber to support these important areas,” said Faraji.

Cantone came to Pfizer through Pharmacia, where she was senior manager of public relations and advocacy development, and had previously worked for Makovsky and Company and the Leukemia Society of America. She is a board member of CancerCare New Jersey and a member of the Healthcare Businesswomen's Association.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...